Caribou Biosciences (CRBU)

• Market cap: $79.1M
• 1 day: -0.16%
• 5 days: 0.11%
• 1 month: -6.81%
• 3 months: -35.05%
• 6 months: -56.81%
• Year to date: -49.35%
• 1 year: -76.56%
• 5 years: -94.79%
• 10 years: -94.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Employees: 147

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

74% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 27

36% more call options, than puts

Call options by funds: $240K | Put options by funds: $176K

23% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 22

6.39% more ownership

Funds ownership: 57.96% [Q3] → 64.35% (+6.39%) [Q4]

3% more funds holding

Funds holding: 128 [Q3] → 132 (+4) [Q4]

10% less capital invested

Capital invested by funds: $103M [Q3] → $93.1M (-$10M) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 253% upside
• Avg. target: $3 253% upside
• High target: $3 253% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 27% 1-year accuracy 46 / 173 met price target

253% upside $3

Buy Maintained

28 Apr 2025